Skip to main content
SpringerLink
Log in

PSA screening: conservative use is cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Low-risk disease was defined as a Gleason score lower than 7 plus a clinical T2a cancer stage or lower.

  2. Selective treatment practices were applied only for screening strategies with PSA thresholds of <10.0 ng/mL because prostate cancer cases diagnosed with PSA levels higher than 10.0 ng/mL would not typically qualify as low risk or as candidates for delayed curative treatment.

References

  1. Roth JA. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncology : 24 Mar 2016. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2015.6275

    PubMed  Google Scholar 

  2. Vickers AJ. Does Prostate-Specific Antigen Screening Do More Good Than Harm? Depends on How You Do It. JAMA Oncology : 24 Mar 2016. Available from: URL: http://dx.doi.org/10.1001/jamaoncol.2015.6276

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PSA screening: conservative use is cost effective. PharmacoEcon Outcomes News 750, 30 (2016). https://doi.org/10.1007/s40274-016-2953-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2953-0

Search

Navigation